

20 Sep 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Biomarin's next chapter; Amgen's obesity plans; Daiichi's new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn's.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 September 2023, including: [BioMarin Pharmaceutical Inc.](#)'s next chapter; [Amgen, Inc.](#)'s obesity plans; [Daiichi Sankyo Co., Ltd.](#)'s new ADC data; [Acelyrin, Inc.](#) hit by clinical failure; and Skyrizi beats Stelara in Crohn's.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[BioMarin's Next Chapter: 'A Financial Growth Story'](#)" - Scrip, 13 Sep, 2023.)

(Also see "[Amgen's Plan To Go Big In Obesity](#)" - Scrip, 12 Sep, 2023.)

(Also see "[Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show](#)" - Scrip, 11 Sep, 2023.)

(Also see "[Acelyrin Goes From Float To Sink](#)" - Scrip, 12 Sep, 2023.)

(Also see "[AbbVie's Skyrizi Bests Stelara Head-To-Head In Crohn's](#)" - Scrip, 12 Sep, 2023.)

[Click here to explore this interactive content online](#) 